
Opinion|Videos|December 6, 2024
Key Insights From the DEBBRAH and HER2CLIMB-02 Studies
Panelists discuss a brief overview of recent data on combination systemic therapies for the treatment of advanced HER2+ breast cancer, including studies such as DESTINY-Breast03, DEBBRAH, HER2CLIMB-02, and EMILIA, and they analyze which patient populations may benefit most from each therapy option based on the available data.
Advertisement
Episodes in this series

- Dr Iyengar: Please provide a brief overview of other recent data in combination systemic therapies for the treatment of advanced RCC.
- DESTINY-Breast03
- DEBBRAH
- HER2CLIMB-02
- EMILIA
- Given the available data, for which patient population do you prefer each therapy option and why?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
3
Withdrawal Planned for Second-Line Lurbinectedin in SCLC Indication
4
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
5





















































